Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

May 15, 2014

 

 

AMGEN INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-12477   95-3540776

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

One Amgen Center Drive

Thousand Oaks, California

  91320-1799
(Address of principal executive offices)   (Zip Code)

805-447-1000

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

Amgen Inc. (the “Company”) held its 2014 Annual Meeting of Stockholders (the “Annual Meeting”) on May 15, 2014. The final results of the voting for each matter submitted to a vote of stockholders at the Annual Meeting are as follows:

Item 1 - Election of Directors

Each of the following 12 nominees for director were elected to serve a one-year term expiring at the Company’s 2015 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier retirement, resignation, disqualification, removal or death.

 

Name

  

Votes For

  

Votes Against

  

Abstain

  

Broker Non-Votes

Dr. David Baltimore

   563,649,606    19,820,369    1,835,592    83,681,552

Mr. Frank J. Biondi, Jr.

   535,546,573    48,073,025    1,917,780    83,449,740

Mr. Robert A. Bradway

   563,021,692    18,194,812    4,284,863    83,485,752

Mr. François de Carbonnel

   568,930,624    14,246,216    2,360,522    83,449,756

Dr. Vance D. Coffman

   526,705,622    56,942,333    1,889,305    83,449,858

Mr. Robert A. Eckert

   578,993,043      4,644,140    1,900,182    83,449,753

Mr. Greg C. Garland

   566,718,807    16,878,743    1,939,810    83,449,759

Dr. Rebecca M. Henderson

   570,011,292    13,725,906    1,800,166    83,449,755

Mr. Frank C. Herringer

   568,847,891    14,706,926    1,982,634    83,449,668

Dr. Tyler Jacks

   570,142,932    13,547,622    1,846,812    83,449,752

Ms. Judith C. Pelham

   574,177,259      9,498,169    1,861,936    83,449,755

Dr. Ronald D. Sugar

   565,093,189    18,115,568    2,328,602    83,449,759

Item 2 - Ratification of Selection of Independent Registered Public Accountants

Ernst & Young LLP was ratified as the Company’s independent registered public accountants for the fiscal year ending December 31, 2014. No Broker Non-Votes resulted from the vote on this proposal.

 

For:

   658,804,125

Against:

       8,029,078

Abstain:

       2,153,915

Item 3 - Advisory Vote to Approve Our Executive Compensation

The advisory vote to approve our executive compensation was approved.

 

For:

   568,795,989

Against:

     12,544,159

Abstain:

       4,513,852

Broker Non-Votes:

     83,133,119

 

2


No other matters were properly submitted for stockholder action.

A copy of the press release announcing the vote results is furnished as Exhibit 99.1 to this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

99.1    Press Release, dated May 15, 2014

 

3


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      AMGEN INC.
Date: May 15, 2014        
      By:  

            /s/ David J. Scott

      Name:   David J. Scott
      Title:   Senior Vice President, General Counsel and Secretary


EXHIBIT INDEX

 

Exhibit

No.

  

Document Description

99.1    Press Release, dated May 15, 2014